Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus
This review article discusses two preventive option for the prevention of RSV in infants: a maternal vaccine and a monoclonal antibody for infants. The FDA …
Ask aRCie
Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged <8 Months - United States, April 2024
This article is about a study on RSV vaccination for pregnant women and their babies in the U.S. It describes how RSV is a common …
Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children - Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024
This report looks at a study on the effectiveness of nirsevimab in preventing respiratory syncytial virus (RSV) illness and hospitalization among Alaska Native children in …
Nirsevimab Frequently Asked Questions
This webpage provides answers to frequently asked questions (FAQs) about nirsevimab, a monoclonal antibody used to prevent RSV in infants and young children. Topics include …
What Is the New RSV Immunization for Infants?
This short video discusses a new FDA-approved product that prevents serious RSV disease in children. It's not a typical vaccine but a monoclonal antibody given …
Multiple Questions About Protection From Respiratory Syncytial Virus
2024
· University of Pennsylvania
This article, written by Stanley A. Plotkin, is about protecting people from respiratory syncytial virus (RSV). It describes key questions about protecting against respiratory syncytial …
Nirsevimab: Alleviating the Burden Of RSV Morbidity in Young Children
2024
· Duke-NUS Medical School,
· KK Women's & Children's Hospital,
· University of New South Wales,
· Macquarie University,
· National Centre for Immunisation Research and Surveillance (NCIRS)
This article reviews the real-world data that supports the effectiveness of nirsevimab, a monoclonal antibody that helps protect young children from RSV. Studies have demonstrated …
Successful Implementation of Nirsevimab and Factors Influencing Uptake in Neonatal Care
This article describes how a hospital successfully used nirsevimab to prevent RSV in newborns. They offered the immunization to 99% of eligible infants, with 71% …
Nirsevimab for Respiratory Syncytial Virus Prophylaxis in Newborns and Infants
2025
· Med Uni Graz
This editorial discusses the burden of respiratory syncytial virus (RSV) infection in young children, particularly infants under 6 months old or in their first RSV …
Nirsevimab and Abrysvo Update for the 2024-2025 Respiratory Season
2024
· Ohio Department of Health
This webpage provides an update on both infant nirsevimab (Beyfortus®) and maternal RSVpreF (Abrysvo™) administration and planning considerations. Infants can be protected against RSV through …